Fujian Aonong Biological Technology Group Incorporation Limited (SHA:603363)
China · Delayed Price · Currency is CNY 3.370
-0.020 (-0.59%)
May 6, 2026, 3:00 PM CST
SHA:603363 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,897 | 8,475 | 8,731 | 19,432 | 21,581 | 18,013 |
Other Revenue | - | - | 31.41 | 25.21 | 31.93 | 25.56 |
| 8,897 | 8,475 | 8,763 | 19,458 | 21,613 | 18,038 | |
Revenue Growth (YoY) | 9.33% | -3.29% | -54.96% | -9.97% | 19.82% | 56.62% |
Cost of Revenue | 8,422 | 7,942 | 8,367 | 20,767 | 20,956 | 18,209 |
Gross Profit | 474.96 | 532.76 | 395.6 | -1,309 | 657.28 | -170.49 |
Selling, General & Admin | 537.56 | 536.94 | 1,129 | 1,071 | 1,073 | 944.98 |
Research & Development | 54.63 | 49.75 | 54.47 | 148.86 | 161.67 | 113.88 |
Other Operating Expenses | -12.81 | -13.92 | 6.05 | 24.6 | 25.76 | -2.41 |
Operating Expenses | 579.37 | 572.78 | 1,245 | 1,291 | 1,285 | 1,101 |
Operating Income | -104.41 | -40.02 | -849.59 | -2,600 | -628.17 | -1,272 |
Interest Expense | - | - | -650.95 | -549.99 | -505.83 | -418.77 |
Interest & Investment Income | 313.64 | 517.86 | 2,043 | 5.19 | 5.94 | 3.76 |
Currency Exchange Gain (Loss) | - | - | -0.1 | -1.41 | -6.85 | -0.34 |
Other Non Operating Income (Expenses) | -308.57 | -311.76 | -53.81 | -52.18 | -75.77 | -20.85 |
EBT Excluding Unusual Items | -99.33 | 166.08 | 488.56 | -3,198 | -1,211 | -1,708 |
Impairment of Goodwill | - | - | -35.39 | -34.66 | -36.51 | -12.14 |
Gain (Loss) on Sale of Investments | 2.46 | -0.16 | -30.32 | -4.07 | -119.76 | -68.86 |
Gain (Loss) on Sale of Assets | -0.23 | 0.36 | 5.59 | -49.74 | -9.41 | -25.09 |
Asset Writedown | -60.94 | -60.94 | -98.51 | -424.3 | -2.76 | -7.63 |
Other Unusual Items | - | - | -245.43 | 29.37 | 84.1 | - |
Pretax Income | -158.04 | 105.34 | 84.49 | -3,682 | -1,295 | -1,822 |
Income Tax Expense | 17.04 | 15.93 | 21.4 | 87.05 | -69.21 | 29.34 |
Earnings From Continuing Operations | -175.08 | 89.41 | 63.09 | -3,769 | -1,226 | -1,851 |
Minority Interest in Earnings | 21.07 | -11.79 | 516.25 | 117.86 | 187.46 | 331.05 |
Net Income | -154.01 | 77.62 | 579.35 | -3,651 | -1,038 | -1,520 |
Net Income to Common | -154.01 | 77.62 | 579.35 | -3,651 | -1,038 | -1,520 |
Net Income Growth | - | -86.60% | - | - | - | - |
Shares Outstanding (Basic) | 2,238 | 2,587 | 865 | 867 | 775 | 650 |
Shares Outstanding (Diluted) | 2,238 | 2,587 | 865 | 867 | 775 | 650 |
Shares Change (YoY) | 68.03% | 199.23% | -0.29% | 11.91% | 19.30% | 3.15% |
EPS (Basic) | -0.07 | 0.03 | 0.67 | -4.21 | -1.34 | -2.34 |
EPS (Diluted) | -0.07 | 0.03 | 0.67 | -4.21 | -1.34 | -2.34 |
EPS Growth | - | -95.52% | - | - | - | - |
Free Cash Flow | 200.26 | -76.95 | -379.46 | 472.23 | -835.31 | -2,184 |
Free Cash Flow Per Share | 0.09 | -0.03 | -0.44 | 0.55 | -1.08 | -3.36 |
Gross Margin | 5.34% | 6.29% | 4.52% | -6.73% | 3.04% | -0.95% |
Operating Margin | -1.17% | -0.47% | -9.70% | -13.36% | -2.91% | -7.05% |
Profit Margin | -1.73% | 0.92% | 6.61% | -18.76% | -4.80% | -8.43% |
Free Cash Flow Margin | 2.25% | -0.91% | -4.33% | 2.43% | -3.86% | -12.11% |
EBITDA | 256.49 | 368.87 | -248.73 | -1,776 | 232.72 | -574.94 |
EBITDA Margin | 2.88% | 4.35% | -2.84% | -9.13% | 1.08% | -3.19% |
D&A For EBITDA | 360.9 | 408.89 | 600.86 | 823.53 | 860.9 | 696.72 |
EBIT | -104.41 | -40.02 | -849.59 | -2,600 | -628.17 | -1,272 |
EBIT Margin | -1.17% | -0.47% | -9.70% | -13.36% | -2.91% | -7.05% |
Effective Tax Rate | - | 15.12% | 25.33% | - | - | - |
Revenue as Reported | - | - | 8,763 | 19,458 | 21,613 | 18,038 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.